Read by QxMD icon Read

Esophageal Cancer Recurance

Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Yuta Ibuki, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada
BACKGROUND: The evaluation of treatment outcomes and detection of prognostic factors after recurrence are very important for tailoring optimal therapies for individual patients with recurrent esophageal cancer. METHODS: We reviewed 133 patients in whom esophageal squamous cell carcinoma (ESCC) recurred after curative surgery, and assessed recurrence patterns, treatment outcomes and prognostic factors. RESULTS: Recurrence in 57 (42.9%), 54 (40...
December 29, 2017: World Journal of Surgery
Kazuki Sudo, Ken Kato, Hiroki Kuwabara, Yusuke Sasaki, Naoki Takahashi, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Natsuko T Okita, Atsuo Takashima, Tetsuya Hamaguchi, Yasuhide Yamada, Yoshinori Ito, Jun Itami, Takahiro Fukuda, Kensei Tobinai, Narikazu Boku
PURPOSE: The purpose of this study was to investigate the utility of surveillance after definitive chemoradiotherapy (dCRT) in patients with squamous cell carcinoma. METHODS: Patients who underwent dCRT for stage II/III (excluding T4) esophageal squamous cell carcinoma were analyzed. First failures following complete response were classified into luminal relapse (LR), regional relapse (RR), distant metastasis (DM), new cancer diagnosed by esophagogastroduodenoscopy (NC-E), and new cancer other than NC-E (NC-O)...
October 28, 2017: Oncology
Manabu Emi, Jun Hihara, Yoichi Hamai, Takaoki Furukawa, Yuta Ibuki, Morihito Okada
BACKGROUND: The prognoses of submucosal esophageal squamous cell carcinoma patients vary. Patients with favorable prognoses may receive less invasive or nonsurgical interventions, whereas patients with poor prognoses or advanced esophageal cancer may require aggressive treatments. We sought to identify prognostic factors for patients with submucosal esophageal squamous cell carcinoma, focusing on lymph node metastasis and recurrence. METHODS: We included 137 submucosal esophageal squamous cell carcinoma patients who had undergone transthoracic esophagectomy with systematic extended lymph node dissection...
October 12, 2017: Annals of Thoracic Surgery
Shuntaro Yoshimura, Kazuhiko Mori, Koichiro Kawasaki, Asami Tanabe, Susumu Aikou, Koichi Yagi, Masato Nishida, Hiroharu Yamashita, Sachiyo Nomura, Masayoshi Fukushima, Hideomi Yamashita, Yasuhiro Yamauchi, Yasuyuki Seto
BACKGROUND: Stereotactic body radiotherapy has been a treatment choice for lung cancer, especially in medically inoperable patients. However, the acute and late toxicity to adjacent organs have been reported as an uncommon but severe adverse effect. CASE PRESENTATION: A 65-year-old male was presented with his back pain and pyrexia. He had been followed up for non-small-cell lung cancer, which was treated by the stereotactic body radiotherapy 4 years prior to the current visit...
August 31, 2017: Surgical Case Reports
Takahiro Nishida, Shinsuke Takeno, Koji Nakashima, Masato Kariya, Haruhiko Inatsu, Kazuo Kitamura, Atsushi Nanashima
INTRODUCTION: Salvage surgery for locoregional failures after definitive chemoradiotherapy (dCRT) for esophageal cancer is widely practiced, but treatment options complementing it are also needed due to the high morbidity and mortality and low rate of curative resection. PRESENTATION OF CASE: A 58-year-old man with a surgical history of right upper lobectomy for lung cancer was diagnosed as having esophageal squamous cell carcinoma. Computed tomography revealed swelling of the lesser curvature lymph node, and it had invaded the stomach, the body and tail of the pancreas and the left gastric artery, splenic artery and celiac artery...
2017: International Journal of Surgery Case Reports
Mohammadreza Seyedmajidi, Maryam Tavassoli, Mojtaba Kianti, Jamshid Vafaeimanesh
BACKGROUND: There have been reports on stent-related vascular erosions about patients with benign or malignant stenosis of the esophagus who received endoscopic stent insertion for palliative intention for oral intake. CASE PRESENTATION: A 61-year-old woman with esophageal cancer located in the middle part of esophagus was treated with esophagectomy. Two years following the surgery, malignant stenosis recurred in the esophagogastric anastomosis. A non-covered self-expanding metal stent (10 cm length with a diameter of 18 mm at expanded state) was inserted...
2016: Caspian Journal of Internal Medicine
Dimitrios E Sigounas, Sandeep Siddhi, John N Plevris
BACKGROUND AND STUDY AIMS: Biodegradable (BD) esophageal stents were recently developed mainly for refractory benign strictures, but experience and available literature are limited. PATIENTS AND METHODS: This was a retrospective observational study. All patients who had BD stents inserted due to refractory benign esophageal strictures or malignant strictures, or were awaiting radical radiotherapy/chemotherapy or neo-adjuvant therapy and esophagectomy between March 2011 and July 2015 were included...
June 2016: Endoscopy International Open
Elżbieta Andrysiak-Mamos, Ewa Żochowska, Agnieszka Kaźmierczyk-Puchalska, Michał Popow, Dorota Kaczmarska-Turek, Janusz Pachucki, Tomasz Bednarczuk, Anhelli Syrenicz
INTRODUCTION: Hypocalcaemia is a common postoperative complication, both after the resection of parathyroid adenoma associated with primary hyperparathyroidism and after total thyroidectomy due to thyroid cancer or nodular goitre. For a few years, in patients with postoperative hypoparathyroidism and severe hypocalcaemia, who cannot discontinue intravenous calcium preparations even with the use of high vitamin D doses, attempts have been made to add recombinant human parathormone (rhPTH) to the treatment schedule...
2016: Endokrynologia Polska
Naoya Yoshida, Yoshifumi Baba, Hironobu Shigaki, Kazuto Harada, Masaaki Iwatsuki, Yasuo Sakamoto, Yuji Miyamoto, Junji Kurashige, Keisuke Kosumi, Ryuma Tokunaga, Masayuki Watanabe, Hideo Baba
BACKGROUND: Esophagectomy following neoadjuvant chemotherapy (NAC) is a standard treatment for resectable advanced esophageal cancer in Japan. However, approximately 10 % of patients with resectable advanced esophageal cancer experience recurrence within 6 months. METHODS: One hundred twenty-eight patients with resectable advanced esophageal cancer underwent NAC between October 2008 and July 2015 in Kumamoto University Hospital. Among them, 82 patients with esophageal squamous cell carcinoma (SCC), who underwent curative esophagectomy without adjuvant treatment, were eligible...
December 2016: International Journal of Clinical Oncology
Aanand D Naik, Lindsey A Martin, Jennifer Moye, Michele J Karel
OBJECTIVES: To identify a taxonomy of health-related values that frame goals of care of older, multimorbid adults who recently faced cancer diagnosis and treatment. DESIGN: Qualitative analysis of data from a longitudinal cohort study of multimorbid cancer survivors. SETTING: Cancer registries from regional Department of Veterans Affairs networks in New England and southeast Texas. PARTICIPANTS: Multimorbid adults who completed interviews 12 months after diagnosis of head and neck, colorectal, gastric, or esophageal cancer and after cancer treatment (N = 146)...
March 2016: Journal of the American Geriatrics Society
Itasu Ninomiya, Koichi Okamoto, Tomoya Tsukada, Jun Kinoshita, Katsunobu Oyama, Sachio Fushida, Harushi Osugi, Tetsuo Ohta
The aim of the present study was to clarify the therapeutic effect of thoracoscopic esophagectomy with radical lymph node dissection based on the recurrence pattern, and identify the risk factors for relapse-free survival in patients with esophageal cancer. The recurrence patterns in 140 patients who underwent complete thoracoscopic radical esophagectomy between January 2003 and December 2012 were investigated. The risk factors for recurrence were examined by univariate and multivariate analysis. Mediastinal recurrence in association with initial lymphatic metastasis was precisely analyzed...
February 2016: Molecular and Clinical Oncology
Yusuke Sato, Satoru Motoyama, Hajime Saito, Yoshihiro Minamiya
There is no doubt that, along with surgery, chemoradiotherapy is an important treatment for esophageal squamous cell carcinoma (ESCC). Patients who respond well to chemoradiotherapy obtain great benefits toward overcoming their cancer, and so a more favorable prognosis. On the other hand, patients who do not respond well have wasted valuable time and experienced severe toxicity and seriously diminished quality of life, only to have their cancer recur with an unfavorable prognosis. For this reason, a reliable biomarker of chemoradiosensitivity in ESCC has long been sought...
2016: European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes
Ansheng Ling, Fanglai Zhu, Ping Wu, Chongwen Fang, Fuliu Cao
OBJECTIVE: To evaluate the safety and prognosis for patients with early esophageal cancer and precancerous lesions after endoscopic submucosal dissection (ESD).
 METHODS: A total of 89 patients were admitted to the Department of internal medicine in the First People's Hospital of Anqing from August 2008 to August 2011. All patients were treated with ESD at the early stage of esophageal cancer and precancerous lesions. The patients' laboratory data and relevant medical history were collected...
January 2016: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
Gabriella Alexandersson von Döbeln, Magnus Nilsson, Gunnar Adell, Gjermund Johnsen, Ingunn Hatlevoll, Jon Tsai, Lars Lundell, Mikael Lund, Pehr Lind
PURPOSE: Curative treatment of esophageal cancer is accompanied by frequent and sometimes severe side effects. However, prospectively collected data on side effects are scarce. The aim of this study was to evaluate if pulmonary function and exercise capacity were affected in the acute setting after neoadjuvant treatment and if there were long-lasting effects after neoadjuvant treatment and surgery. We also aimed to investigate whether the addition of radiation therapy to chemotherapy would aggravate side effects...
May 2016: Practical Radiation Oncology
Denggui Wen, Liwei Zhang, Xiaoling Wang, Yongwei Li, Caifeng Ma, Xu Liu, Junli Zhang, Xiaoduo Wen, Yi Yang, Fuzhi Zhang, Shijie Wang, Baoen Shan
BACKGROUND AND AIM: This study aimed to estimate the time to precursor progression and to identify significant predicators. METHODS: One hundred thirty-three precursor and 311 normal cases detected in a population-based screening were surveyed for 5.5 years. Precursor progression was defined as worsening of dysplasia or development of a new precursor. Time to precursor progression was estimated by the Kaplan-Meier method. Significant predicators were estimated by Cox proportional regression...
December 2015: Journal of Gastroenterology and Hepatology
Takashi Takenoya, Yukari Kobayashi, Kouichi Suda, Kazuki Shimizu, Masahiro Kikuichi
A 62-year-old man with lower rectal cancer underwent abdominoperineal resection and dissection of the lateral pelvic lymph nodes. The cancer was staged at pT3pN0cM0, pStage II and did not show recurrence. Two years later, the patient had dysphagia and was diagnosed with esophageal cancer based on upper gastrointestinal endoscopy. Positron emission tomography-computed tomography (PET/CT) performed to detect distant metastasis revealed fluorodeoxyglucose (FDG) uptake in the left obturator lymph nodes, indicating rectal cancer recurrence...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Khaldoun Almhanna, Sarah Hoffe, Jonathan Strosberg, William Dinwoodie, Kenneth Meredith, Ravi Shridhar
BACKGROUND: Neoadjuvant concurrent chemoradiotherapy (CCRT) has become the standard treatment for esophageal cancer (EC) in North America. The cisplatin/5-flurouracil (5-FU) combination has been the most commonly used regimen. For the last 15 years we incorporated a daily continuous infusion of 5-FU and 2 doses of cisplatin into our neoadjuvant CCRT for potentially resectable EC. PATIENTS AND METHODS: Between July 1997 and June 2012, 129 patients with locally advanced EC (T3 or N1 and higher), received neoadjuvant CCRT with cisplatin 75 mg/m(2) on day 1 and day 29 and continuous infusion of 5-FU (225 mg/m(2)/day) on the days of radiation...
February 2015: Journal of Gastrointestinal Oncology
Naoyuki Nogami, Nagio Takigawa, Katsuyuki Hotta, Yoshihiko Segawa, Yuka Kato, Toshiyuki Kozuki, Isao Oze, Daizo Kishino, Keisuke Aoe, Hiroshi Ueoka, Shoichi Kuyama, Shingo Harita, Toshiaki Okada, Shinobu Hosokawa, Koji Inoue, Kenichi Gemba, Takuo Shibayama, Masahiro Tabata, Mitsuhiro Takemoto, Susumu Kanazawa, Mitsune Tanimoto, Katsuyuki Kiura
BACKGROUND: Although cisplatin-based chemotherapy combined with thoracic irradiation (TRT) is a standard treatment for unresectable, locally advanced non-small cell lung cancer (NSCLC), this treatment outcome has remained unsatisfactory. We had previously conducted a phase I trial of cisplatin plus S-1, an oral 5-fluorouracil derivative, and TRT, which were safe and effective. METHODS: In this phase II trial, 48 patients with stage III NSCLC received cisplatin (40mg/m(2) on days 1, 8, 29 and 36) and S-1 (80mg/m(2) on days 1-14 and 29-42) and TRT (60Gy)...
February 2015: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Hiroshi Nemoto, Genshu Tate, Takahiro Umemoto, Taketo Matsubara, Hiroki Mizukami, Mitsuo Saito, Gaku Kigawa, Akihiko Matsumiya, Junichi Tanaka
A 69-year-old man was diagnosed with advanced esophageal cancer(well-differentiated squamous cell carcinoma). Neoadjuvant chemotherapy consisting of nedaplatin and 5-fluorouracil(5-FU)was initiated. After two courses of chemotherapy, the patient was judged to have achieved a clinical complete response. The patient then decided against undergoing surgery and opted instead to continue with the chemotherapy, receiving five courses in total. However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011...
July 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Cui Li Lin, Kenneth Meredith, Jason Klapman
GOALS: The goal of this study was to determine the luminal recurrence rate of asymptomatic patients undergoing annual surveillance esophagogastroduodenoscopy (EGD). BACKGROUND: Current guidelines recommend surveillance EGD in postesophagectomy patients with esophageal cancer if there is clinical suspicion of local recurrence. However, many patients undergo annual surveillance EGD despite the recommendations to the contrary. STUDY: A query was performed of all patients who underwent esophagectomy between January 2000 and April 2010 at Moffitt Cancer Center...
September 2015: Journal of Clinical Gastroenterology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"